Aripiprazole: a treatment for severe coprolalia in "refractory" Gilles de la Tourette syndrome.

Full Abstract

Coprolalia is one of the most distressing symptoms in Gilles de la Tourette syndrome. We report on a 28-year-old man with severe coprolalia at the forefront of symptoms, which had a dramatic impact on his social and professional life and that did not fluctuate for years. Moreover, he presented hypersensitivity to neuroleptics. The use of aripiprazole, as a last resort, induced a 75% of improvement of his symptoms with good tolerance. This suggests that aripiprazole constitutes a valuable therapeutic in coprolalia. Moreover, its biochemical class specificity makes it an alternative for patients hypersensitive to other classes of neuroleptics. 2007 Movement Disorder Society

Author information

Author/s: Ben Djebara, Mouna (M); Worbe, Yulia (Y); Schüpbach, Michael (M); Hartmann, Andreas (A);

Affiliation: Centre d'Investigation Clinique, Fédération de Neurologie, Paris, France.

Journal and publication information

Publication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't

Journal: Movement disorders : official journal of the Movement Disorder Society (Mov Disord), published in United States. (Language: eng)

Reference: 2008-Feb; vol 23 (issue 3) : pp 438-40

Dates: Created 2008/03/04; Completed 2008/05/08;

PMID: 18067182, status: MEDLINE (last retrieved date: 2/18/2009)

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.